TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17138832
Drug: Control (Con)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Con) with 3 g/day L-carnitine
Study: 15855571
Drug: 5 microg
Normalized name: Digoxin 125 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg subcutaneous exenatide b.i.d.
Study: 15855571
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg subcutaneous exenatide b.i.d.
Study: 8313807
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during normoglycemia
Study: 8313807
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during hyperglycemia
Study: 21491144
Drug: Technosphere® Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Insulin (TI) inhalation powder
Study: 12702132
Drug: Interferon-alfa-2a (IFN)
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alfa-2a (IFN) regimen Group B: 9 MU daily for 2 weeks, 3 MU daily for 22 weeks, then 3 MU three times a week for the last 24 weeks
Study: 7888013
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion
Study: 3831962
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (500 micrograms)
Study: 3831962
Drug: Intramuscular pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pentazocine (30 mg)
Study: 8138651
Drug: Intramuscular pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pentazocine
Study: 30312799
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (1 g given 2 hours before incision, repeated at 3 hours and 6 hours postoperatively)
Study: 30312799
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA (1 g administered 10 minutes before incision, repeated at 3 hours and 6 hours postoperatively)
Study: 20427749
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (up to 40,000 IU/day for 28 weeks, then 10,000 IU/day for 12 weeks, followed by 0 IU/day) with calcium (1,200 mg/day)
Study: 20427749
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (up to 40,000 IU/day)
Study: 20427749
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving high-dose vitamin D)
Study: 16095500
Drug: Donor antibody
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor antibody titer
Study: 12360162
Drug: COER-verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-verapamil hydrochloride (240 mg titrated to 360 mg)
Study: 12360162
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg titrated to 20 mg)
Study: 15047641
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg titrated to 100 mg)
Study: 7013303
Drug: Metoclopramide (cerucal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (cerucal, 3 x 10 mg p.o.)
Study: 31743809
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + Gln (Gln 20 g/d for 6 d and maltodextrin 8%/200 mL for 20 min)
Study: 30651194
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection (SA)
Study: 28728560
Drug: Patient-oriented education
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-oriented education and medication management intervention
Study: 26469896
Drug: Amiodarone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone therapy group (n = 122 patients)
Study: 26469896
Drug: Metoprolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol therapy group (n = 129 patients)
Study: 19800193
Drug: CRT ON
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT ON (active treatment)
Study: 19800193
Drug: CRT OFF
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT OFF (control treatment)
Study: 16950955
Drug: Cocoa husk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa husk supplement
Study: 10899847
Drug: Vaccine lot
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine lot E005
Study: 10899847
Drug: Vaccine lot
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine lot E003
Study: 10899847
Drug: Vaccine lot
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine lot E005 and E003
Study: 8101082
Drug: Broxaterol (B)
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (B) at 0.75 mg
Study: 8101082
Drug: Broxaterol (B)
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (B) at 1.25 mg
Study: 8101082
Drug: Broxaterol (B)
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (B) at 2.50 mg
Study: 8101082
Drug: Broxaterol (B)
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (B) at 1.25 mg, 3 times a day for 1 month
Study: 3794304
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg atropine sulfate
Study: 6113682
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pirenzepine
Study: 31550941
Drug: Specific BTK
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific BTK inhibitors
Study: 26307162
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bacillus Calmette‐Guérin (40 mg)
Study: 26307162
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose bacillus Calmette‐Guérin (80 mg)
Study: 24396757
Drug: Diclofenac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.0 mg/kg
Study: 17396066
Drug: alpha-Lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-Lipoic acid and acetyl-L-carnitine
Study: 12162470
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg, 15 mg, 30 mg
Study: 12162470
Drug: Indomethacin (Indo-ER)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (Indo-ER) 75 mg once daily
Study: 7533343
Drug: FK506/prednisone (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506/prednisone (double therapy)
Study: 7533343
Drug: FK506/azathioprine/prednisone (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506/azathioprine/prednisone (triple therapy)
Study: 323086
Drug: Calcium dobesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesylate, 250 mg three times a day (period B)
Study: 31558866
Drug: Ropivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine group (7.5 mg/mL ropivacaine infiltration)
Study: 31558866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline 5 mL infiltration)
Study: 29028286
Drug: Doppler-guided goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler-guided goal-directed fluid therapy (GDFT)
Study: 28440045
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg BID
Study: 27206567
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg QD
Study: 21795446
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg BID and QD
Study: 16255390
Drug: Group cue-exposure
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cue-exposure program to drug-related stimuli (12 treatment sessions, 3 times weekly)
Study: 9935221
Drug: Preoperative radio‐chemo‐thermo‐therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative radio‐chemo‐thermo‐therapy (RCTT)
Study: 9935221
Drug: Radio‐chemo‐therapy (RCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio‐chemo‐therapy (RCT) without hyperthermia (control group)
Study: 7778631
Drug: Tocolysis (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolysis (intravenous magnesium sulfate and/or oral or subcutaneous beta-sympathomimetics)
Study: 7778631
Drug: Short-term intravenous
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intravenous magnesium alone
Study: 6985697
Drug: Molsidomine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (0.03 mg/kg IV) during exercise-induced angina
Study: 6985697
Drug: Molsidomine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (0.03 mg/kg IV) during pacing-induced angina
Study: 6985697
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg three times daily)
Study: 31221197
Drug: ML-Adaptive Boosting
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-Adaptive Boosting
Study: 31221197
Drug: ML-random forest
Normalized name: Fortesta
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ML-random forest
Study: 31221197
Drug: ML-adaptive boosting
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-adaptive boosting
Study: 31221197
Drug: ML-Markov chain
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-Markov chain Monte Carlo generalized linear mixed model
Study: 26433456
Drug: GMT 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMT 2.0 treatment
Study: 19117888
Drug: Monthly parenting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly parenting newsletter (12 issues) containing information on emotional development, parent-child interaction, and play.
Study: 16009958
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy plus two 5-day chemotherapy courses (fluorouracil 350 mg/m2/d and leucovorin 20 mg/m2/d) in the first and fifth week of RT
Study: 16009958
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy plus four postoperative chemotherapy courses
Study: 16009958
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy and chemotherapy plus postoperative chemotherapy
Study: 11888223
Drug: Hypnosis (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (standardized eight-session hypnosis treatment)
Study: 11888223
Drug: Relaxation (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation (standardized eight sessions of Jacobson's relaxation treatment)
Study: 2085082
Drug: Propofol alone
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol alone (12‐15 mg/kg/h)
Study: 2085082
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with fentanyl supplementation (6‐9 mg/kg/h)
Study: 30945124
Drug: Disease-modifying anti-rheumatic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying anti-rheumatic drugs (DMARDs)
Study: 24696369
Drug: Stop-smoking medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop-smoking medication
Study: 24696369
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (preferred by 85.2% of medication users)
Study: 23643001
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10 mg/kg (intravenous injection slowly before skin incision) followed by infusion of normal saline until postoperative 12 hours
Study: 23643001
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 10 mg/kg (intravenous injection slowly before skin incision) followed by infusion of tranexamic acid 1 mg/(kg·h) until postoperative 12 hours
Study: 19998582
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (Acnez)
Study: 15140569
Drug: Psychometric assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychometric assessment after EMDR treatment
Study: 11796084
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole (400 mg) and praziquantel (40 mg/kg)
Study: 9494455
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics plus intranasal beclomethasone (336 micrograms/day)
Study: 9494455
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics plus intranasal placebo
Study: 10303911
Drug: Mass mammography
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass mammography screening (specific details on dosage and duration not available)
Study: 27621414
Drug: Syringes (0.2‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringes (0.2‐ and 0.5‐mL increments)
Study: 27621414
Drug: Overall dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall dosing error
Study: 22122880
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of daytime benzodiazepines
Study: 43682
Drug: 90% Alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90% Alcohol (10-6 ml)
Study: 24659797
Drug: Ponesimod 20
Normalized name: ponesimod 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 20 mg
Study: 24659797
Drug: Ponesimod 10
Normalized name: ponesimod 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 10 mg
Study: 24659797
Drug: Ponesimod 40
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod 40 mg
Study: 29024325
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg p-synephrine
Study: 29024325
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg p-synephrine
Study: 29024325
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg p-synephrine
Study: 20809735
Drug: Biodegradable cages
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable cages (70/30 poly(l‐lactide‐co‐d,l‐lactide) (PLDLA))
Study: 15585598
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (Epi) during hyperinsulinemic euglycemic clamp studies
Study: 15585598
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (Epi)
Study: 10996882
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus group therapy (TG+)
Study: 10996882
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (TG-)
Study: 8629922
Drug: Bolus intrathecal
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intrathecal injection of 50 micrograms baclofen
Study: 1309633
Drug: PI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI regimen (cisplatin 80 mg/m2 dl and ifosfamide 2 g/m2 d 1, 2, 3, q 3‐4 wks)
Study: 1309633
Drug: PV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PV regimen (cisplatin 80 mg/m2 d 1 and vindesine 3 mg/m2 d 1, 8, 15, q 3‐4 wks)
Study: 6152804
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg megestrol acetate and 5 mg estradiol valerate
Study: 6152804
Drug: Microencapsulated megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated megestrol compound
Study: 20691834
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acids (1 g/d)
Study: 19026871
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 1% diphenhydramine with 1:100,000 epinephrine
Study: 20307730
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 19026871
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine combined with 1% diphenhydramine with 1:100,000 epinephrine
Study: 15781499
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) with fentanyl (7-15 microg/kg) and morphine infusion
Study: 15781499
Drug: High Thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Thoracic Epidural Anesthesia (HTEA) with fentanyl (5-7 microg/kg) and epidural infusion of ropivacaine 0.2% and fentanyl 2 microg/mL until postoperative Day 3
Study: 12519833
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg/d orally)
Study: 1346410
Drug: Cyclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (5 mg/kg per day for 12 weeks)
Study: 29960287
Drug: Qinbei Qingfei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinbei Qingfei Yiqi (QBQFYQ) granules plus usual treatment
Study: 19303966
Drug: Low-dose supplemental
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose supplemental vitamins E plus C
Study: 19303966
Drug: Medium-dose supplemental
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose supplemental vitamins E plus C
Study: 19303966
Drug: High-dose supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose supplemental vitamins E plus C
Study: 15156934
Drug: Cranberry supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry supplement (400 mg, 3 times a day for 4 weeks)
Study: 29885904
Drug: Midazolam 5
Normalized name: midazolam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 5 mg
Study: 27817037
Drug: Total recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total recombinant follicle‐stimulating hormone (rFSH) dose
Study: 24053627
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid administered 24 hours after endoscopic procedure for 14 days
Study: 19820872
Drug: Vaginal estriol
Normalized name: estriol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estriol therapy for 14 days
Study: 19820872
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no estriol therapy)
Study: 9227927
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b combined with cytarabine (20 mg per square meter per day for 10 days, plus hydroxyurea 50 mg per kilogram per day)
Study: 9227927
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b alone (plus hydroxyurea 50 mg per kilogram per day)
Study: 7954535
Drug: Furosemide, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 25 mg/day
Study: 7954535
Drug: Torasemide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide, 10 mg/day
Study: 3664553
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with codeine
Study: 28058750
Drug: Evogliptin 5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 5 mg after 52 weeks
Study: 28058750
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg after 52 weeks
Study: 26232505
Drug: Galactooligosaccharide (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactooligosaccharide (1.7 g)
Study: 17876014
Drug: Erlotinib (Erl)
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (Erl) 150 mg daily combined with Bevacizumab (Bev) 10 mg/kg every 2 weeks
Study: 17876014
Drug: Bevacizumab (Bev)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Bev) 10 mg/kg every 2 weeks
Study: 16420077
Drug: Tiagabine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4 mg/day initiated, flexibly dosed to a maximum of 16 mg/day)
Study: 29893592
Drug: D-aspartic acid
Normalized name: (3S)-3-methyl-D-aspartic acid
DrugBank: D-Aspartic Acid (DB02655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-aspartic acid (DAA) 3 g/day for 2 weeks
Study: 29893592
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 g/day for 2 weeks
Study: 12860833
Drug: Aldosterone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone with L‐NMMA
Study: 16520409
Drug: L‐NMMA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA alone